Document Detail


Biologicals dramatic advances in the treatment of psoriasis.
MedLine Citation:
PMID:  16533166     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Innovations in biotechnology have made possible the development of several new systemic therapies for psoriasis - the "biologicals", a new group of compounds including monoclonal antibodies, fusion proteins and recombinant proteins. These novel biotechnological advances potentially offer designer drugs, which interfere with specific targets in the pathophysiological network of psoriasis and are thus much safer. The therapeutic strategy of biologicals is based on the knowledge derived from pathogenetic studies, which have focused on targeting disease relevant T-cell- or mediator-systems. Important targets include inactivation of soluble mediators such as tumor-necrosis-factor-alpha, the blockade of receptors for cytokines, adhesion molecules and the interference with T-cell activation by antigen-presenting cells. In addition, recombinant cytokines are able to modulate the immunological balance of this chronic inflammatory skin disease. Currently, up to forty agents are under investigation for the treatment of psoriasis. Four of these agents, alefacept, efalizumab, etanercept and infliximab have already impacted on routine clinical practice. Current developments in the treatment of psoriasis with biologicals are reviewed.
Authors:
Dagmar Wilsmann-Theis; Saskia Martin; Michael Reber; Bartlomiej Kwiek; Thomas Bieber; Natalija Novak
Related Documents :
18923446 - The human antimicrobial peptide ll-37 suppresses apoptosis in keratinocytes.
9362536 - Evidence that singlet oxygen-induced human t helper cell apoptosis is the basic mechani...
10587516 - Interleukin-11 therapy selectively downregulates type i cytokine proinflammatory pathwa...
7528926 - Keratinocyte expression of b7-1 in transgenic mice amplifies the primary immune respons...
21967766 - Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis ...
1373746 - The state of differentiation of cultured human keratinocytes determines the level of in...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  12     ISSN:  1381-6128     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2006  
Date Detail:
Created Date:  2006-03-14     Completed Date:  2007-03-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  989-99     Citation Subset:  IM    
Affiliation:
Department of Dermatology, University of Bonn, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / pharmacology,  therapeutic use*
Antibodies, Monoclonal / pharmacology,  therapeutic use
Cell Adhesion
Clinical Trials as Topic
Humans
Immunologic Factors / pharmacology,  therapeutic use*
Interleukin-10 / pharmacology,  therapeutic use
Psoriasis / drug therapy*,  immunology
Recombinant Fusion Proteins / pharmacology,  therapeutic use
Recombinant Proteins / pharmacology,  therapeutic use
T-Lymphocytes / drug effects,  immunology
Tumor Necrosis Factor-alpha / antagonists & inhibitors,  immunology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/IL10 protein, human; 0/Immunologic Factors; 0/Recombinant Fusion Proteins; 0/Recombinant Proteins; 0/Tumor Necrosis Factor-alpha; 0/efalizumab; 0/infliximab; 130068-27-8/Interleukin-10

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapy.
Next Document:  Role of opioid antagonists in the treatment of women with glucoregulation abnormalities.